OpenLoop

What kind of data actually improves patient outcomes?

Personal data.

Most healthcare data tells patients what is happening.
Personal data helps explain why it is happening.

Why energy levels feel depleted.
Why sleep quality keeps declining.
Why stress is impacting recovery.

That's what whole-health diagnostics uncover.

When patients receive insights that are genuinely personal to them they become active participants in their care, which can lead to better outcomes.

Not just results. Clarity. Ownership. A personalized path forward.

OpenLoop's end-to-end, white-label infrastructure gives organizations the tools to deliver that experience.

Offer whole-health diagnostics built around 120+ clinically selected biomarkers.

Ready to build a more connected patient experience? Contact us today.

Men are living nearly 6 years less than women.

Yet 61% of men say they’d be more likely to go to their annual check-up if seeing a doctor was more convenient.

Here’s the disconnect:

The modern health-conscious man is not ignoring his health. He's tracking workouts, logging macros, monitoring his sleep.

But his testosterone? Cortisol? Inflammatory markers? Vitamin D deficiency? Insulin resistance?

Most men have never seen those numbers.

This is because because traditional healthcare hasn’t made it accessible, proactive, or easy enough.

That gap between daily health habits and clinical insight is leading to missed opportunities for earlier intervention.

This Men’s Health Month, organizations can help close that gap with whole-health diagnostics that deliver actionable insights — without the friction of traditional care.

Testosterone. Cortisol. Inflammation. Metabolic health. Nutrient deficiencies.

The kind of data that give men visibility into what’s happening beneath the surface.

With OpenLoop’s white-label infrastructure, organizations can launch whole-health testing and care programs that make proactive care more accessible, personalized, and actionable.

The FDA will hold a PCAC meeting July 23-24 to give recommendations on 7 peptides.

So what happens next?

The meeting itself does not approve reclassification—it’s a recommendation.
Any change would still require a formal FDA rulemaking process before taking effect.

But in the meantime, this is the window to prepare for what could come next.

If Category 2 peptides move to Category 1, it shifts how compounding is assessed and what’s required operationally.

The difference will come down to readiness.

In our latest blog, we break down:
→ What this shift actually means under 503A
→ What would (and wouldn’t) change operationally
→ Why FDA review still continues
→ How to be ready for any peptide classification

Read the full breakdown👉 https://hubs.li/Q04jfmp30

We’ve got Expo only guest passes! Just 20 left 👀

OpenLoop Health will be at the SHRM Annual Conference & Expo (June 16–19), and we’re offering FREE Exhibitor Expo Only Guest Passes for prospective partners.

Here’s what you’ll get:
✔️ Admission to the SHRM Expo, including the opening reception
✔️ Access to exhibitor showcases and networking opportunities

What’s not included:

Educational or keynote sessions
Evening events (like SHRM After Hours)
Exhibitor setup/teardown access

We have just 20 passes available and would love to connect with organizations exploring new ways to elevate employee health and wellness programs.

Interested?

Reach out to our Channel Partnerships Manager, Lucy DeAngelo, to request your pass 👇
[email protected]

See you in Orlando. 🌴

Healthcare isn’t moving toward whole-health.
It’s already there.

A projected $1.1T+ shift toward personalized, connected care is underway.
Spanning hormone health, weight management, longevity, and beyond.

(Grandview Research, Personalized Medicine Market Size Industry Report, 2025-2033)

In a market where demand is obvious and evolving, the challenge becomes ex*****on at scale.

Delivering whole-health care doesn’t live in a single solution, it comes from alignment across clinical care, programs, patient support, and operations.

That level of coordination introduces complexity, but that’s exactly where differentiation is built.

And where the right infrastructure makes the difference.

OpenLoop powers the engine behind whole health, connecting clinical care, services, and patient support into one scalable system.

Don’t just meet demand—deliver on it. At scale.

How do you turn peptide therapy interest into a live, revenue-generating program?

Everyone’s talking about peptide therapy.
Patients are asking for it. Competitors are launching it.

And healthcare leaders are feeling the pressure.

For most organizations, it’s not a lack of demand, it’s the complexity:
Unclear regulations. Clinical risk. Operational lift.

So programs get delayed… or never launch at all.

Don’t let complexity stall your growth.

OpenLoop Health’s latest blog breaks down what it actually takes to launch and scale a peptide therapy program.

Inside you’ll learn:

✔️ The current regulatory status of peptides
✔️ How to navigate clinical + compliance requirements
✔️ How to build a peptide therapy program

✔️ How OpenLoop can bring your peptide therapy program to market faster

Don’t let complexity stall your growth.

Get the full guide here👉
https://hubs.li/Q04gw_yp0